ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment

Inflammatory Bowel Disease

ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment

J Crohns Colitis

Adamina M, Kienle P, Chaparro M, Verstockt B, Minozzi S, Allocca M, Atreya R, Avellaneda N, Barreiro-De Acosta M, Battat R, Bettenworth D, Blumenstein I, Brown SR, Burke JP, Caprioli F, Casanova MJ, Christou N, De Buck Van Overstraeten A, Doherty G, Eder P, El-Hussuna A, Ellul P, Fantini MC, Furfaro F, Greuter T, Hazel K, Holubar S, Kapizioni C, Kopylov U, Leong RW, Leventoglu S, Limdi JK, Noor NM, Papaconstantinou I, Peros G, Pouillon L, Reenaers C, Saibeni S, Schmidt C, Sousa P, Stassen LPS, Uzzan M, Vieujean S, Visser E, Kucharzik T, Gisbert JP, Myrelid P

doi: 10.1093/ecco-jcc/jjag072

Inflammatory Bowel Disease

Mechanistic insights into FMT for the treatment of ulcerative colitis: analysis of the STOP-Colitis trial

J Crohns Colitis

Quraishi MN, Moakes CA, Yalchin M, Blackwell C, Segal J, Ives NJ, Magill L, Manzoor SE, Gerasimidis K, McMullan C, Mathers J, Horniblow R, Loi S, Kaur M, Loman NJ, Sharma N, Hawkey P, McCune V, Quick J, Nicholls S, McMurray C, Nichols B, Svolos V, Raguideau S, Kerbiriou C, Oo YH, Beggs AD, Crees N, Hansen R, Hart AL, Gaya DR, Quince C, Iqbal TH

doi: 10.1093/ecco-jcc/jjag006

Inflammatory Bowel DiseaseFurther Publications

Filgotinib Is an Effective and Safe Treatment Option for Difficult-To-Treat Ulcerative Colitis: Real-World Evidence of the Dutch Initiative on Crohn and Colitis (ICC) Registry

United European Gastroenterol J

Naber MR, van der Meulen AE, Voorneveld PW, Veltkamp SHC, van Bodegraven AA, Bodelier A, Mujagic Z, Pierik M, Verleye LMM, Duijvestein M, Bouwknegt DG, Visschedijk MC, Srivastava N, West RL, Oldenburg B, Löwenberg M, van Schaik FDM, Dutch ICC Registry

doi: 10.1002/ueg2.70141

Inflammatory Bowel Disease

Clinical features and therapeutic requirements of perianal disease in adult patients with ulcerative colitis: the PERICO study of the ENEIDA registry

Inflamm Bowel Dis

Guasch M, Calafat M, Gargallo-Puyuelo CJ, De Francisco R, Moraleja I, Vega P, de Castro L, Labarga F, Mesonero F, Castro-Poceiro J, Ponferrada-Díaz A, Brunet-Mas E, Sesé E, Ramos L, Quiñones M, Ruiz-Cerulla A, Castro B, Zabana Y, Iglesias E, Latras I, Varela P, Ricart E, Madero L, Elosua A, Vicente L, Lorente R, Betoré E, Roig C, Mañosa M, Domènech E, PERICO-ENEIDA Study of the GETECCU

doi: 10.1093/ibd/izag120

Inflammatory Bowel Disease

New Diagnostic Criteria for Acute Severe Ulcerative Colitis in the Modern Treatment Era: A Modified Delphi Consensus by REFINED-ASUC

Clin Gastroenterol Hepatol

Raine T, Peyrin-Biroulet L, Begun J, Biedermann L, Blumenstein I, Cheifetz AS, Colombel JF, Dulai PS, Gecse KB, Jairath V, Nakase H, Panaccione R, Reinisch W, Verstockt B, Higgins PDR

doi: 10.1016/j.cgh.2026.07.011

Inflammatory Bowel Disease

Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

Lancet Gastroenterol Hepatol

Wu K, Zheng C, Cao Q, Ding Y, Gao X, Zhong J, Chiu CT, Zhang H, Wang X, Wang B, Liang J, Liu X, Zhou Y, Xu B, Kim TO, Shen X, Chen D, Chen W, Liu Y, Shen J, Liu F, Ding X, Zhan Q, Chou JW, Zeng S, Lin Y, Ying L, Chen X, ENLIGHT UC Study Group

doi: 10.1016/S2468-1253(25)00198-0

Inflammatory Bowel Disease

Risk of serious infection, myocardial infarction, stroke, and thromboembolic events in patients in the United States with ulcerative colitis treated with tofacitinib compared with biologic treatments.

Inflamm Bowel Dis

Rubin DT, Schreiber S, Peyrin-Biroulet L, Danese S, Gianfrancesco MA, Soonasra A, Sidhu S, Vranic I, Shelbaya A, Gruben D, Wei Y, Winthrop KL, Curtis JR, Regueiro MD, Dubinsky MC

doi: 10.1093/ibd/izag142

Inflammatory Bowel Disease

Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis

Inflamm Bowel Dis

Rubin DT, Danese S, Nakase H, Ungaro RC, Wolf DC, Alekseeva O, Petersen A, Liu Z, Mehra D, Jain A, Osterman MT, Krakovich A, Riolo JV, DeBoer E, Appio J, Sinh P, Cree BAC, Cohen JA, Irving P

doi: 10.1093/ibd/izaf319

Inflammatory Bowel Disease

Plasma Proteomics for Risk Prediction and Therapeutic Target Discovery in Crohn's Disease and Ulcerative Colitis

Inflamm Bowel Dis

Gan X, Zhang Y, Zhang Y, Ye Z, Yang S, Xiang H, Huang Y, Wu Y, Zhang Y, Qin X

doi: 10.1093/ibd/izaf325

Related content

ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment

Mechanistic insights into FMT for the treatment of ulcerative colitis: analysis of the STOP-Colitis trial

Filgotinib Is an Effective and Safe Treatment Option for Difficult-To-Treat Ulcerative Colitis: Real-World Evidence of the Dutch Initiative on Crohn and Colitis (ICC) Registry

Clinical features and therapeutic requirements of perianal disease in adult patients with ulcerative colitis: the PERICO study of the ENEIDA registry

New Diagnostic Criteria for Acute Severe Ulcerative Colitis in the Modern Treatment Era: A Modified Delphi Consensus by REFINED-ASUC

Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

Risk of serious infection, myocardial infarction, stroke, and thromboembolic events in patients in the United States with ulcerative colitis treated with tofacitinib compared with biologic treatments.

Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis

Plasma Proteomics for Risk Prediction and Therapeutic Target Discovery in Crohn's Disease and Ulcerative Colitis